Results 61 to 70 of about 19,815 (203)

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem, Abdul Qayyum, Abid Jamil, Abid Taj, Ahmad Khalid, Ammara Tahir, Ijaz Shah, Mahwish Khan, Mubashar Naqvi, Mudassar Iqbal, Muhammad Abbad, Muhammad Ferhan, Muhammad Khalid, Najeeb ur-Rehman, Riaz ul-Haq, Shahid Baig, Tanveer Akhtar, Tariq Gill, Weng Qin, Zafar Iqbal   +19 more
core   +1 more source

A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]

, 2015
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core   +1 more source

MXene‐Based Electrochemiluminescence (ECL) Biosensors: A Review on Analyte Detection and Diagnostic Applications

MedComm – Biomaterials and Applications, Volume 4, Issue 4, December 2025.
This review highlights recent advances in MXene‐based electrochemiluminescence (ECL) biosensors, showcasing their exceptional sensitivity and versatility in detecting biomolecules, pathogens, and environmental pollutants. The integration of MXenes significantly enhances ECL signal amplification, paving the way for next‐generation diagnostic and ...
Kai Zhang
wiley   +1 more source

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

Acta Médica Portuguesa, 2019
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment.
Antonio Almeida, Francesca Pierdomenico, Blanca Polo Guerrero, Filipa Saraiva, Ana Montalvão, Jorge Coutinho, Mário Mariz, Teresa Melo, Maria João Santos, Alexandra Pereira, Nuno Cerveira   +10 more
doaj   +1 more source

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) [PDF]

Leukemia, 2002
We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity.
Fischer, T., Reifenrath, C., Hess, G. R., Corsetti, M. T., Kreil, S., Beck, J., Meinhardt, P., Beltrami, G., Schuch, B., Gschaidmeier, H., Hehlmann, R., Hochhaus, A., Carella, A., Huber, C.   +13 more
openaire   +3 more sources

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Chronic myeloid leukemia: past, present, future [PDF]

Einstein (São Paulo), 2011
The discovery of the Philadelphia chromosome in 1960, and of theBCR-ABL oncogene in 1984, enabled the development in subsequentyears of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history ...
Patricia Weinschenker Bollmann, Auro del Giglio   +1 more
doaj   +4 more sources

Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. [PDF]

PLoS ONE, 2012
BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia.
Ludovic Belle, France Bruck, Jacques Foguenne, André Gothot, Yves Beguin, Frédéric Baron, Alexandra Briquet   +6 more
doaj   +1 more source

Dasatinib and azacitidine followed by haploidentical stem cell transplant for chronic myeloid leukemia with evolving myelodysplasia: A case report and review of treatment options. [PDF]

, 2017
BACKGROUND: CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging.
Ottmann, Oliver
core   +2 more sources

Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients [PDF]

Blood, 1993
Abstract We report here the results of polymerase chain reaction (PCR) for bcr- abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 ...
K, Miyamura, T, Tahara, M, Tanimoto, Y, Morishita, K, Kawashima, Y, Morishima, H, Saito, S, Tsuzuki, K, Takeyama, Y, Kodera   +9 more
openaire   +3 more sources